How could the acquisition of prenatal testing by LabCorp affect Medicare?
Increased prenatal testing volume could expand Medicare's utilization of lab services. The acquisition of Myriad Genetics' Prenatal Health testing business by Labcorp is expected to expand access to advanced screening solutions and increase the volume of tests performed. Since Labcorp is a major provider of laboratory services, this increased capacity and expanded access could lead to a higher utilization of Medicare's reimbursement channels for prenatal testing. The transaction is expected to preserve uninterrupted patient access to these tests while adding approximately $160 million in revenue to Labcorp in year one.
- Effect
- Mild positive
- How direct
- Brind's reasoning
- When
- Within weeks
- The story
- Gone quiet
How it reaches Medicare
-
Myriad Genetics announced it is selling its Prenatal Health testing business to LabCorp. The transaction includes tests such as Prequel®, Foresight®, SneakPeek®, and FirstGene®. LabCorp will acquire the business for $210 million in cash, plus the value of the inventory.
The full event1independent outlet -
As Labcorp integrates the prenatal testing portfolio, which previously served over 600,000 patients in the last twelve months, the expanded volume of tests performed by Labcorp could increase the utilization of Medicare's reimbursement channels for these services.
No report states this step directly. Brind drew it from the reporting on each side of it, so treat it as an informed guess.
-
US federal health insurance
Everything about Medicare
Tap any step to see the evidence behind it.
The facts so far
As reported. Each one links to where it comes from.
- Myriad Genetics sold its Prenatal Health testing business to Labcorp for $210 million in cash, plus inventory value.manilatimes.net
- The Prenatal Health portfolio was used by over 600,000 patients over the last twelve months.manilatimes.net
- Labcorp expects the transaction to add approximately $160 million in revenue in year one.manilatimes.net
- The transaction is expected to preserve uninterrupted patient access to prenatal tests.manilatimes.net
Why it matters
For Medicare, the increased volume of prenatal testing represents a shift in utilization patterns for diagnostic services. As Labcorp integrates the testing portfolio, the increased demand for these advanced screening solutions could lead to higher claims volume and changes in how Medicare manages its reimbursement for reproductive genetics services.
Labcorp is a major player in the laboratory services industry, and its financial health is structurally dependent on major payers like Medicare. The successful integration and expansion of this specific testing business could significantly alter the scope of services available to Medicare beneficiaries, while also impacting the overall revenue stream of the acquiring entity.
What we don't know yet
- Will Medicare coverage policies change to accommodate the expanded scope of Labcorp's prenatal testing?
- How quickly will Labcorp be able to fully integrate the Prenatal Health business to realize the expected revenue growth?
What would change this answer
Who else could feel it
Other possible ripples from the same event.
- Applied DNA SciencesPossibleLabCorp's expanded diagnostic capacity may increase competitive pressure on Applied DNA Sciences
- Quest DiagnosticsPossibleQuest Diagnostics may face increased competition from LabCorp's expanded prenatal testing portfolio.
- FDAPossibleLabcorp's expanded prenatal testing portfolio may require FDA review
Reporting
- manilatimes.netOct 20
Keep going
Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.